Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fesoterodine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Fesoterodine. Displaying page 1 of 1.
    EudraCT Number: 2010-024181-22 Sponsor Protocol Number: A0221095 Start Date*: 2011-05-18
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG F...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) HU (Completed) DE (Completed) FI (Completed) GR (Completed) LT (Completed) AT (Completed) DK (Completed) SK (Completed) BG (Prematurely Ended) NO (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018254-12 Sponsor Protocol Number: A0221090 Start Date*: 2010-03-16
    Sponsor Name:Pfizer, Inc
    Full Title: A LOCAL, MULTICENTRE, OPEN-LABEL, EXTENSION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE FLEXIBLE DOSE REGIMEN IN ELDERLY PATIENTS WITH OVERACTIVE BLADDER
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence (Some patients will also have urgency urinary incontinence (UUI)).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006451-39 Sponsor Protocol Number: A0221046 Start Date*: 2008-02-20
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) LT (Completed) ES (Completed) HU (Completed) GR (Completed) EE (Completed) LV (Completed) SK (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-022475-55 Sponsor Protocol Number: A0221047 Start Date*: 2012-07-20
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A 24-WEEK RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDI...
    Medical condition: Neurogenic Detrusor Overactivity (NDO).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10029279 Neurogenic bladder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed) FI (Completed) SK (Completed) GB (Completed) ES (Completed) GR (Completed) FR (Completed) NL (Completed) BE (Completed) RO (Ongoing) DK (Prematurely Ended) DE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004124-23 Sponsor Protocol Number: A0221058 Start Date*: 2009-01-29
    Sponsor Name:Pfizer Limited
    Full Title: A 12 week, multicentre, open label study to evaluate the efficacy, tolerability and safety of a Fesoterodine flexible dose regimen in patients with overactive bladder
    Medical condition: Treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007087-17 Sponsor Protocol Number: A0221045 Start Date*: 2008-06-13
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK
    Full Title: A 24-WEEK, MULTICENTRE TRIAL, COMPRISING A 12-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE FOLLOWED BY A 12-WEEK OPEN-LABEL PHASE, TO EVALUATE THE EFFICACY AND SAFETY OF...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence (Some patients will also have urgency urinary incontinence (UUI)).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) GB (Completed) BE (Completed) SK (Completed) AT (Completed) DE (Completed) DK (Completed) PT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006935-38 Sponsor Protocol Number: A0221008 Start Date*: 2007-04-16
    Sponsor Name:Pfizer Inc. NYO-685-21-14,685 3rd Avenue, NEW YORK, NY 10017. US
    Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) HU (Completed) DK (Completed) CZ (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004555-11 Sponsor Protocol Number: A0221009 Start Date*: 2008-01-23
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE AS AN "ADD-ON" THERAPY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS UNDER MONOTHERAPY ...
    Medical condition: overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) BE (Completed) NL (Completed) GR (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004161-24 Sponsor Protocol Number: A0221066 Start Date*: 2015-03-24
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: An Open-Label, Dose-Escalating Study of the Pharmacokinetics, Safety and Tolerability of Fesoterodine in Pediatric Overactive Bladder Patients Aged 8-17 Years
    Medical condition: Overactive bladder (OAB) and Neurogenic Detrusor Over activity
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005350-21 Sponsor Protocol Number: A0221064 Start Date*: 2009-02-03
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED CROSSOVER STUDY OF THE EFFICACY OF FESOTERODINE IN INCREASING URETHRAL PRESSURE IN STRESS URINARY INCONTINENCE PATIENTS
    Medical condition: Stress urinary incontinence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066218 Stress urinary incontinence LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-024179-18 Sponsor Protocol Number: A0221094 Start Date*: 2011-05-31
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A 14 WEEK RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTRE STUDY OF FESOTERODINE 8 MG IN OVERACTIVE BLADDER PATIENTS WITH SUB-OPTIMAL RESPONSE TO TOLTERODINE 4 MG ER
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) DE (Completed) CZ (Completed) FI (Completed) GR (Completed) BG (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006070-22 Sponsor Protocol Number: A0221007 Start Date*: 2007-03-16
    Sponsor Name:Pfizer Inc
    Full Title: A 12-WEEK, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTS OF FESOTERODINE ON TREATMENT SATISFACTION AND SYMPTOM RELIEF IN OVERACTIVE BLADDER PATIENTS
    Medical condition: Overactive bladder (OAB) is a symptom complex defined by the International Continence Society (ICS) as the symptoms of urgency, with or without urgency incontinence, usually with frequency and noct...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000476-13 Sponsor Protocol Number: SP738 Start Date*: 2004-08-10
    Sponsor Name:Schwarz Biosciences GmbH
    Full Title: LONG-TERM OPEN-LABEL EXTENSION TRIAL FOR SUBJECTS COMPLETING THE PHASE 3 TRIAL OF FESOTERODINE (SP583) FOR THE TREATMENT OF OVERACTIVE BLADDER SYNDROME
    Medical condition: overactive bladder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023851-27 Sponsor Protocol Number: AMRPhD1 Start Date*: 2012-06-14
    Sponsor Name:Kings College Hospital NHS Foundation Trust
    Full Title: A 12 week, multi centre, open label study to evaluate the effect of fesoterodine flexible dosing regimen on the sexual function of women with overactive bladder.
    Medical condition: sexual function of women with overactive bladder syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004872 10040482 Sexual function abnormal LLT
    18.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004192-41 Sponsor Protocol Number: A0221109 Start Date*: 2020-09-03
    Sponsor Name:Pfizer
    Full Title: LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR ...
    Medical condition: Urinary Bladder, Neurogenic
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005295-33 Sponsor Protocol Number: S54913 Start Date*: 2013-03-08
    Sponsor Name:UZ Leuven-Department of Urology
    Full Title: Monocentric, open-label, phase III study that compares the efficiency and tolerance between intravesical oxybutynin and oral fesoterodine in children (5-16y) with neurogenic detrusor overactivity.
    Medical condition: children with neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10041524 Spina bifida PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 07:14:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA